https://www.pharmaradar360.com/article/medtronic-completes-acquisition-of-scientia-vascular-seamlessly-integrating-acce-469fadaf5d680ba6Pharma Surgeen2026-06-12T15:00:00.000ZMedtronic completes acquisition of Scientia Vascular, seamlessly integrating access and therapeutic portfolios for neurovascular carehttps://www.pharmaradar360.com/article/customizing-clinical-trial-content-for-boston-scientific-s-device-trials-790c6b3ef6210811Pharma Surgeen2026-06-12T14:39:53.000ZCustomizing Clinical Trial Content for Boston Scientific’s Device Trialshttps://www.pharmaradar360.com/article/decision-medical-devices-given-exceptional-use-authorisations-1da59e34d8e20cdePharma Surgeen2026-06-12T12:20:47.000ZDecision: Medical devices given exceptional use authorisationshttps://www.pharmaradar360.com/article/gsk-s-momelotinib-granted-orphan-drug-designations-in-the-us-and-eu-for-vexas-sy-1694c5206207a0bfPharma Surgeen2026-06-12T12:00:00.000ZGSK’s momelotinib granted Orphan Drug Designations in the US and EU for VEXAS syndromehttps://www.pharmaradar360.com/article/3f9e7a9025bdde1dPharma Surgeen2026-06-12T11:06:32.000ZΕξάρθρωση κυκλώματος παράνομης παραγωγής και εμπορίας φαρμάκωνhttps://www.pharmaradar360.com/article/abbvie-presents-new-data-at-eha-2026-congress-for-venclexta-venclyxto-venetoclax-3b4a161b7fe700dePharma Surgeen2026-06-12T07:00:00.000ZAbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Resultshttps://www.pharmaradar360.com/article/316121edb04a2d63Pharma Surgeen2026-06-12T06:30:00.000Zテセントリク、局所進行の食道がんにおける根治的化学放射線療法後の維持療法として適応拡大申請https://www.pharmaradar360.com/article/tecentriq-filed-for-additional-indication-as-maintenance-therapy-following-defin-1fa0a27aed6401bcPharma Surgeen2026-06-12T06:30:00.000ZTecentriq Filed for Additional Indication as Maintenance Therapy Following Definitive Chemoradiotherapy in Locally Advanced Esophageal Cancerhttps://www.pharmaradar360.com/article/engaging-the-immune-system-in-aml-a-new-frontier-in-the-pursuit-of-durable-outco-d02e217580fe003dPharma Surgeen2026-06-12T06:00:00.000ZEngaging the immune system in AML: A new frontier in the pursuit of durable outcomeshttps://www.pharmaradar360.com/article/yakkyokukata-pdg-march-2026-news-posted-37fe8e4d60071c6fPharma Surgeen2026-06-12T03:00:00.000Z[YAKKYOKUKATA]PDG March 2026 News postedhttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-53b8c714285fda74Pharma Surgeen2026-06-12T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-b91f9f126fc98f05Pharma Surgeen2026-06-12T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b91463-crore-consolidated-revenue-and-e2-82-b9517-9-crore-of-ab0c6a7d0ee16b9ePharma Surgeen2026-06-12T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-e290a01f83ae62d2Pharma Surgeen2026-06-12T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-b4598f9556a5c711Pharma Surgeen2026-06-12T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-b4aa6c75c64a14a2Pharma Surgeen2026-06-12T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-a437c1b793b50f13Pharma Surgeen2026-06-12T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-b10f42434166996bPharma Surgeen2026-06-12T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-announces-launch-of-its-everolimus-tablets-1-mg-generic-of-zortress-fd25b4b76c0c05d1Pharma Surgeen2026-06-12T00:00:00.000Znatco announces launch of its everolimus tablets 1 mg generic of zortresshttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-bb368824d094d91ePharma Surgeen2026-06-12T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-8f29b3638dc762ecPharma Surgeen2026-06-12T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-3007e4f465e638c8Pharma Surgeen2026-06-12T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/adcock-ingram-completes-delisting-from-jse-natco-pharma-acquires-35-75-stake-871e0f35ede81809Pharma Surgeen2026-06-12T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/home-page-9f86474e2db0d54dPharma Surgeen2026-06-12T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/on-behalf-of-respighi-bidco-s-p-a-offer-document-filed-with-consob-related-to-th-380b67a2582d061dPharma Surgeen2026-06-11T21:06:01.000ZOn behalf of Respighi BidCo S.p.A – Offer Document filed with CONSOB related to the voluntary totalitarian tender offer launched by Respighi BidCo S.p.A. on the ordinary shares of Recordati S.p.A.https://www.pharmaradar360.com/article/adial-pharmaceuticals-announces-acquisition-of-azora-therapeutics-and-up-to-64-m-f644b61d84c6ab12Pharma Surgeen2026-06-11T18:04:07.000ZAdial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financinghttps://www.pharmaradar360.com/article/why-do-i-pheel-this-way-episode-2-explores-social-life-support-and-self-advocacy-ceec7e4a3c55f8bbPharma Surgeen2026-06-11T17:48:35.000ZWhy Do I Pheel This Way? Episode 2 Explores Social Life, Support and Self-Advocacy for Teens with Phenylketonuriahttps://www.pharmaradar360.com/article/china-clears-alphamab-s-her2-bispecific-antibody-in-gastric-cancer-3f6eb07577d4a273Pharma Surgeen2026-06-11T16:00:00.000ZChina clears Alphamab’s HER2 bispecific antibody in gastric cancerhttps://www.pharmaradar360.com/article/przed-uzenie-dodatkowego-swiadectwa-ochronnego-mog-oby-dziesieciokrotnie-zwieksz-d578bc7567a1bb55Pharma Surgeen2026-06-11T15:09:31.000ZPrzedłużenie dodatkowego świadectwa ochronnego mogłoby dziesięciokrotnie zwiększyć inwestycje w badania i rozwój w Europiehttps://www.pharmaradar360.com/article/adial-pharmaceuticals-announces-acquisition-of-azora-therapeutics-and-up-to-64-m-ae0f2a5fc3d31b8fPharma Surgeen2026-06-11T14:45:37.000ZAdial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financinghttps://www.pharmaradar360.com/article/regulation-of-medical-devices-in-northern-ireland-d5934f909d804c54Pharma Surgeen2026-06-11T14:22:09.000ZRegulation of medical devices in Northern Irelandhttps://www.pharmaradar360.com/article/clinical-research-career-pathways-survey-c5cb0f498f105b4aPharma Surgeen2026-06-11T13:24:55.000ZClinical Research Career Pathways Surveyhttps://www.pharmaradar360.com/article/0-2-2026-5f90624d30545e24Pharma Surgeen2026-06-11T12:46:26.000ZΔιακήρυξη υπ. Αριθ. 0/2/2026 Ηλεκτρονικού Ανοικτού κάτω των Ορίων Διαγωνισμού για την Προμήθεια μονάδων αποθήκευσης και υπηρεσιών μετάπτωσηςhttps://www.pharmaradar360.com/article/regulation-of-ai-in-healthcare-10f88174ca8f7445Pharma Surgeen2026-06-11T11:00:01.000ZRegulation of AI in Healthcarehttps://www.pharmaradar360.com/article/relmada-therapeutics-appoints-cns-drug-development-veteran-michael-quirk-as-seni-205d264caf7d86c9Pharma Surgeen2026-06-11T11:00:00.000ZRelmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Programhttps://www.pharmaradar360.com/article/research-national-commission-into-the-regulation-of-ai-in-healthcare-research-en-21bb1db32095ead8Pharma Surgeen2026-06-11T11:00:00.000ZResearch: National Commission into the Regulation of AI in Healthcare: research, engagement and call for evidence findingshttps://www.pharmaradar360.com/article/merck-animal-health-to-acquire-targan-2f6b4330db3ef43bPharma Surgeen2026-06-11T10:45:58.000ZMerck Animal Health to Acquire TARGANhttps://www.pharmaradar360.com/article/l-industrie-pharmaceutique-appelle-le-g7-a-investir-dans-l-innovation-pour-stimu-eae612766dc14463Pharma Surgeen2026-06-11T09:35:08.000ZL'industrie pharmaceutique appelle le G7 à investir dans l'innovation pour stimuler la compétitivité, la résilience et la croissancehttps://www.pharmaradar360.com/article/imuldosa-c-s-sol-in-130mg-26ml-5mg-ml-d387045970c061acPharma Surgeen2026-06-11T08:58:50.000ZΑνάκληση παρτίδων του φαρμακευτικού προϊόντος IMULDOSA C/S.SOL.IN 130MG/26ML (5MG/ML)https://www.pharmaradar360.com/article/medical-devices-ask-for-a-regulatory-advice-meeting-from-the-mhra-7c78aa5bda84204bPharma Surgeen2026-06-11T07:48:47.000ZMedical devices: ask for a regulatory advice meeting from the MHRAhttps://www.pharmaradar360.com/article/pharmaceutical-industry-calls-on-g7-to-invest-in-innovation-to-drive-competitive-5108affff37cb403Pharma Surgeen2026-06-11T06:55:15.000ZPharmaceutical industry calls on G7 to invest in innovation to drive competitiveness, resilience, and growthhttps://www.pharmaradar360.com/article/fda-grants-priority-review-for-roche-s-tecentriq-for-a-certain-type-of-stage-iii-93694650d74349fdPharma Surgeen2026-06-11T05:00:00.000ZFDA grants Priority Review for Roche’s Tecentriq for a certain type of stage III colon cancerhttps://www.pharmaradar360.com/article/shinsa-list-of-approved-medical-devices-april-2004-to-september-2025-ac2f2ddaaf2000e9Pharma Surgeen2026-06-11T03:00:00.000Z[SHINSA]List of Approved Medical Devices: April 2004 to September 2025https://www.pharmaradar360.com/article/otsuka-foods-biwako-research-institute-develops-oishisa-lens-an-ai-system-that-p-fa2f8da3448e035dPharma Surgeen2026-06-11T00:00:00.000ZOtsuka Foods’ Biwako Research Institute Develops “Oishisa LENS,” an AI System That Predicts Flavor Profiles and Recipes to Secure Expertise Transfer and Enhance Product Design 58 Years After the Brand’s Launch, Preserving Bon Curry’s Signature Taste for the Next Generationhttps://www.pharmaradar360.com/article/importance-of-blood-donations-during-summer-c8cdce3bb62cb2f3Pharma Surgeen2026-06-11T00:00:00.000ZImportance of Blood Donations During Summerhttps://www.pharmaradar360.com/article/acrp-fellow-encourages-flexibility-creativity-and-persistence-in-clinical-resear-d8c21a61db1638e9Pharma Surgeen2026-06-10T21:26:50.000ZACRP Fellow Encourages Flexibility, Creativity, and Persistence in Clinical Researchhttps://www.pharmaradar360.com/article/anmat-consolido-su-participacion-en-los-principales-espacios-internacionales-de-a6014d1a9ea04878Pharma Surgeen2026-06-10T18:26:07.000ZANMAT consolidó su participación en los principales espacios internacionales de regulación farmacéuticahttps://www.pharmaradar360.com/article/three-deals-in-six-days-everest-builds-late-stage-apac-portfolio-b6144bc862643edfPharma Surgeen2026-06-10T16:00:00.000ZThree deals in six days: Everest builds late-stage APAC portfoliohttps://www.pharmaradar360.com/article/3-fragen-an-unser-neues-boardmitglied-lauren-mcnamer-general-manager-von-lilly-s-dd58111caa29b7eaPharma Surgeen2026-06-10T15:17:39.000Z3 Fragen an unser neues Boardmitglied: Lauren McNamer, General Manager von Lilly Switzerlandhttps://www.pharmaradar360.com/article/zepbound-tirzepatide-and-shaquille-o-neal-launch-national-campaign-after-nba-leg-493743c6f37b4aacPharma Surgeen2026-06-10T13:30:00.000ZZepbound® (tirzepatide) and Shaquille O'Neal launch national campaign after NBA legend learns the obstructive sleep apnea he has lived with for years is treatablehttps://www.pharmaradar360.com/article/celebrating-our-aspen-aspire-leadership-graduates-97af457c2334448aPharma Surgeen2026-06-10T13:20:53.000ZCelebrating our Aspen Aspire Leadership Graduateshttps://www.pharmaradar360.com/article/antengene-s-atg-201-gains-ind-clearance-in-china-a351e0b64f6dcca3Pharma Surgeen2026-06-10T13:00:00.000ZAntengene’s ATG-201 gains IND clearance in Chinahttps://www.pharmaradar360.com/article/allergan-aesthetics-releases-the-aesthetics-evolution-what-consumers-really-want-5a87b0ed5b11656cPharma Surgeen2026-06-10T12:00:00.000ZAllergan Aesthetics Releases 'The Aesthetics Evolution: What Consumers Really Want' Highlighting Consumer Motivations and Expectations in Aestheticshttps://www.pharmaradar360.com/article/opportunities-for-patients-and-the-public-to-be-involved-in-the-work-of-the-mhra-8495d3dc8baed1e0Pharma Surgeen2026-06-10T11:26:08.000ZOpportunities for patients and the public to be involved in the work of the MHRAhttps://www.pharmaradar360.com/article/company-sellas-life-sciences-df8a2c2b7cd408acPharma Surgeen2026-06-10T10:31:56.000ZCompany - Sellas Life Scienceshttps://www.pharmaradar360.com/article/ibento-ibento-workshop-on-new-approach-methodologies-nams-held-following-iccr-20-4329d3d1643c3425Pharma Surgeen2026-06-10T03:00:00.000Z[IBENTO][IBENTO]Workshop on New Approach Methodologies (NAMs) Held following ICCR-20​https://www.pharmaradar360.com/article/update-on-patient-enrollment-in-phase-2-study-of-enzomenib-for-acute-leukemia-325c6873bf0725d8Pharma Surgeen2026-06-10T02:30:00.000ZUpdate on Patient Enrollment in Phase 2 Study of Enzomenib for Acute Leukemiahttps://www.pharmaradar360.com/article/how-summer-heat-can-impact-migraines-35cc0dc7e26973e7Pharma Surgeen2026-06-10T00:00:00.000ZHow Summer Heat Can Impact Migraineshttps://www.pharmaradar360.com/article/fda-approves-lilly-s-ebglyss-lebrikizumab-lbkz-for-one-maintenance-dose-every-ei-9d4fc7426a3911aaPharma Surgeen2026-06-09T22:18:00.000ZFDA approves Lilly's EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis